Illumina
VC Fund
San Diego, United States
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission-critical to have solutions that are not only innovative, but flexible, scalable, andcomplete with industry-leading support and service. As a company that places a high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, they strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.David R. Walt, Satnam Alag, Larry Bock, and John Stuelpnagel co-founded Illumina in San Diego, California in 1998.
- Total investments:
- 24
- Last investment:
- Lead investor:
- 21%
Last updated:
For AI agents: llms.txt
Industries Illumina invests in
Stages Illumina invests in
Countries Illumina invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alex Aravanis
|
|||
|
Anthony Flannery
|
|||
Doohyun Park
|
|||
Greg Apker
|
|||
Ilaria Grizzi
|
|||
| See all 16 contacts → | |||
Investment Focus
Industry
- Biotechnology 16 (67%)
- Health Care 11 (46%)
- Health Diagnostics 6 (25%)
- Genetics 4 (17%)
- Life Science 4 (17%)
Stage
- Seed 4 (17%)
- Series A 4 (17%)
- Series C 3 (13%)
- Funding Round 3 (13%)
- Pre-Seed 2 (8%)
Country
- United States 14 (58%)
- United Kingdom 3 (13%)
- Canada 2 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Alex Aravanis
Chief Technology Officer & Senior Vice President
|
Chief Technology Officer & Senior Vice President | Total investments: 13 | Find email | |
|
Anthony Flannery
Sr Director, Nanofabrication Development
|
Sr Director, Nanofabrication Development | Total investments: 0 | Find email | |
|
Doohyun Park
Senior Sales Specialist
|
Senior Sales Specialist | Total investments: 0 | Find email | |
|
Greg Apker
Director of Global Commercial Analytics and Data Science
|
Director of Global Commercial Analytics and Data Science | Total investments: 0 | Find email | |
|
Ilaria Grizzi
Director, System Integration
|
Director, System Integration | Total investments: 0 | Find email | |
| See all 16 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Myome
|
Myome helps identify genes that cause disease and act based on leading science. The data is secure, portable, and reusable throughout life. | Venture - Series Unknown / Dec 11, 2025 | |
Pillar Biosciences
|
Pillar Biosciences is prized with its patent-pending targeted sequencing technology platform and a proprietary data analysis toolkit, which achieves high sensitivity and specificity with clinical samples. The platform provides a fast, simple and affordable targeted sequencing method for NGS-based oncology testing. The start-up has also released itsbeta version of Lung & Colon Cancer Somatic Mutation Panel and BRCA1 & BRCA2 Germline Mutation Panel to cancer centers and clinical testing companies in the US and China for validation studies.The company was founded in 2014 and is headquartered in Natick, Massachusetts. | $34.5M / Venture - Series Unknown / May 27, 2025 | |
Truveta
|
Truveta is a healthcare data platform collaboration with physicians, life science researchers, and others in the healthcare community. | $320M / Series C / Jan 13, 2025 | |
Cache
|
Biomolecules are the next bits of the 21st century. So we're developing the first wet operating system for storing, accessing, and computing biomolecules at scale to make them widely accessible and useful. We're enabling the storage and access to the whole data universe—digital and biological—forever so that we don't have to deleteor dispose of anything ever again. | Seed / May 07, 2024 | |
Mantra Bio
|
Mantra Bio develops a novel next-generation, targeted therapeutics based on its proprietary platform for engineering Targeted Exosome Vehicles (TEVs). The Company's REVEAL platform, which integrates computational and wet biology, and automation, leverages the diversity of exosomes to enable the rational design of therapeutics directed at awide range of tissue and cellular targets. Mantra Bio has also established a scalable biomanufacturing process and related technologies to ensure this new class of therapeutics is reproducibly made at high purity. | $9M / Series A / Jan 04, 2023 | |
Mable (Neurolytic Healthcare)
|
Neurolytic Healthcare provides personalized medicine for neurological conditions. Neurolytic Healthcare collects and extracts insights from a combination of genetic and biomarker data to enhance diagnosis and help clinicians decide on optimal treatment strategies for neurological conditions.The company delivers digitally and genomically-drivenmedical devices to improve the current treatment of migraine and other neurological disorders, including a diagnostic support tool, pharmacogenetic test, and a mobile app for migraine event prediction. | Pre-Seed / Jul 27, 2022 | |
SomaLogic
|
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscantechnology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado. | $375M / Post-IPO Equity / Sep 01, 2021 | |
Concr
|
ConcR’s software integrates a breadth of data into a model to predict how and why a cancer therapy will behave | $691.5K / Pre-Seed / Apr 01, 2021 | |
|
Concr
|
ConcR’s software integrates a breadth of data into a model to predict how and why a cancer therapy will behave | $654K / Seed / Apr 01, 2021 | |
Ginkgo Bioworks
|
Ginkgo Bioworks is a biotechnology firm. It is a developer of biological engineering products and custom microbes across multiple markets. It designs, engineer, develops, tests, and licenses organisms. It discovers molecules in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. It also provides probiotic bacteria toprotect the body from dangerous infections, and it generates libraries of molecules. It serves cultured ingredients, carbon mitigation, probiotics, and natural product discovery markets. | $70M / Series F / May 28, 2020 | |
| See all 24 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Illumina invest in?
Illumina invests primarily in Biotechnology, Health Care and Health Diagnostics startups, most often at Seed and Series A stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Illumina?
Public channels for Illumina include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Illumina?
The team at Illumina includes Alex Aravanis (Chief Technology Officer & Senior Vice President), Anthony Flannery (Sr Director, Nanofabrication Development) and Doohyun Park (Senior Sales Specialist), among 16 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
